Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23162895 | 0.98 | AKR1B1 (0.61) | AKR1B1MAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL4808780 | 0.90 | AKR1B1 (0.68) | AKR1B1HSD17B1 | |
| SCHEMBL1346675 | 0.87 | AKR1B1 (0.52) | AKR1B1MAOAMAOBPRKCIRXRA | |
| SCHEMBL8790426 | 0.86 | MAOA (0.54) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL15897523 | 0.83 | AKR1B1 (0.55) | AKR1B1RXRARXRBRXRG | |
| SCHEMBL17486940 | 0.81 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL5527444 | 0.81 | RXRB (0.65) | AKR1B1RXRARXRBRXRG | |
| SCHEMBL19996854 | 0.81 | RXRB (0.60) | AKR1B1RXRARXRBRXRG | |
| SCHEMBL9335049 | 0.81 | NPC1 (0.52) | MAOAMAOBPRKCI | |
| SCHEMBL29521703 | 0.80 | BAZ2B (0.50) | MAOAMAOBPRKCIHSD17B1BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-0817772-B1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6110947-A | AN ANALGESIC AGENT FOR TREATING STROKE, ABDOMINAL PAIN; AS ANTIINFLAMMATORY, DIURETIC, ANESTHETIC OR NEUROPROTECTIVE AGENTS | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-5952369-A | ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE | PFIZER INC (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1996030339-A1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5428042-A | Analgesics, antiinflammatory agents | DR LO ZAMBELETTI S.P.A. (IT) | 1995-06-27 | — | — | US | disclosed |
| EP-0594611-A1 | NOVEL 1-(2H-1-OXO-3,4-DIHYDRONAPHTYL-6)-ACETYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE | Dr. Lo. Zambeletti S.p.A. (IT) | 1994-05-04 | — | — | EP | disclosed |
| WO-1991017116-A1 | NOVEL 1-(2H-1-OXO-3,4-DIHYDRONAPHTYL-6)-ACETYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-11-14 | — | — | WO | disclosed |
| EP-0333315-B1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | Dr. Lo. Zambeletti S.p.A. (IT) | 1991-06-12 | — | — | EP | disclosed |
| US-4994450-A | Side effect reduction | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-02-19 | — | — | US | disclosed |
| EP-0333315-A1 | Azacyclic compounds, processes for their preparation and their pharmaceutical use | Dr. Lo. Zambeletti S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | AKR1B1 2178/4885MAOA 2249/4885MAOB 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.